Located on the north western outskirts of Sydney at Glenorie, Bioproperties' vaccine manufacturing facility has large commercial capacity for animal vaccine and pharmaceutical production under code Good Manufacturing Practice (cGMP) Australian standards. The facility is fully licensed as a Class 1 Sterile Biologicals manufacturing site through the Australian Pesticides & Veterinary Medicines Authority (APVMA) (Licence number 1061) and also has an AQIS and OGTR licence. The Company also carries out limited contract manufacture of human and animal vaccines.

Development and Scale-up

Bioproperties has highly developed production scale-up and trial batch cGMP manufacturing capabilities at Glenorie, RMIT in Melbourne and Eimeria research & development at University of Melbourne.


Warehousing of final product and national and international distribution is handled from the head office at Ringwood in Victoria.


Bioproperties is signatory to the Australian Packaging Covenant Organisation (APCO) and is reviewing all packaging and on-site waste with the aim of becoming more sustainable. Significant reductions in on-site office and lunchroom waste have already occurred and packaging to customers is being reviewed to have more reusable, recyclable or compostable materials where possible. The specific areas being addressed are aiming to:

Environmental Emergencies for 11-15 Moores Rd, Glenorie